Portage BiotechPRTG
About: Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
Employees: 7
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 14 [Q3] → 14 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
8.32% less ownership
Funds ownership: 12.45% [Q3] → 4.13% (-8.32%) [Q4]
72% less capital invested
Capital invested by funds: $861K [Q3] → $239K (-$622K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for PRTG.
Financial journalist opinion



